NED Archives

State Acts/Emergency Scheduling 2015

• Act 54 SB2882 SD2 HD2 CS Bill 4-28-14
• 2015 Emergency Scheduling Action 1-7-15
• Act-195-SB1131-Relating to the Uniform Controlled Substances Act -7-2-15

Federal Scheduling Actions 2015

• 2015 Emergency Controlled Substance Scheduling Action – 1-7-2015
• Fed-Scheduling-Action-2-24-15-naloxegol-removed-from-CII
• Federal-Scheduling-Action-Acetyl-Fentanyl-Schedule-I-7-30-15
• Fed-Scheduling-Action-11-12-15-eluxadoline-Schedule-IV-effective-12-14-15

Federal Scheduling Actions 2016

• 2016 Emergency Controlled Substance Scheduling Action – 5-6-2016
• 2016 Emergency Controlled Substance Scheduling Action – 5-18-2016
• Fed-Scheduling-Action-9-30-16-thiafentanil
• Federal-Scheduling-Action-9-30-16-brivaracetam
• 2016 Notice of Emergency Scheduling of Furanyl Fentanyl – 10-07-2016
• Emergency Controlled Substance Scheduling Action – 5F-ADB – 11-15-2016
• Emergency Controlled Substance Scheduling Action – 3,4-dichloro – 11-15-2016

Federal Scheduling Actions 2017

• Federal Scheduling Action substituted cathinones
• Emergency scheduling Cumyl-4-cn binaca
• Federal Scheduling Action dronabinol

Federal Scheduling Actions 2018-2020

• notice of Federal Scheduling Action brexanolone 2020
• notice of emergency Scheduling Action etizolam and flualprazolam
• notice of Federal Scheduling Action new controlled substances October 2021
• notice of Federal Scheduling Action new fentanyls october 12 2020
• notice of Federal Scheduling Action epidiolex August 21 2020
• notice of Federal Scheduling Action norfentanyl April 17 2020
• notice of Federal Scheduling Action solriamfetol january 7 2020
• Act 256 2019/SB536 Prescription requirements related to schedule II drugs
• federal scheduling action of fentanyl analogs August 2019
• Act 190 became law 07-01-2018 (relating to scheduling actions of substituted cathinones,, cumyl-4-cn-binaca and dronabinol) Note: Archives contain previous emergency scheduling actions of these chemicals
• Federal Scheduling Action Epidiolex October 2018

2018 and 2019 NEW & CHANGES TO THE LAW

• Act 95 2019/SB 1263 Amends the Uniform Controlled Substance Act by updating Schedule V and amending requirements for electronic prescriptions, for consistency with federal law.
• Act 230 2019/SB1486 Amends Electronic Prescription Accountability system (HI-PDMP)
• Act 251 2019/HB665 Exceptions to query of Electronic Prescription Accountability System (HI-PDMP)
• Act 256 2019/SB536 Prescription requirements related to schedule II drugs
• Act 95 2019/SB 1263 Addition of FDA approved CBD drugs to Schedule V
• Act 066/Senate Bill 505(2017) Effective 07-01-18. Requirement for policy or and written agreements to engage in an informed consent process between the prescribing provider and qualifying opioid therapy patient. Related Resource: Hawaii Department of Health, Patient Informed Consent Form also the Hawaii Revised Statute (HRS) 329.38-5
• Act 151/House Bill 1602 Effective 08-01-18. Requires the inclusion of a label warning of the risks of addiction and death on the packaging of any opioid drug dispensed by a health care professional or pharmacist.
• Act 153/Senate Bill 2646 Effective 07-01-18 Pertains to practitioner utilization requirements of the PDMP
• Act 190/House Bill 2385 Effective 07-01-18. Relating to scheduling actions of substituted cathinones, cumyl-4-cn-binaca and dronabinol